SEC Company Response from CHEMOKINE THERAPEUTICS CORP (CIK 0001092959) — Apr 25, 2005
CHEMOKINE THERAPEUTICS CORP (CIK 0001092959)
Date: April 25, 2005 · CIK: 0001092959 · Accession: 0001077048-05-000225
AI Filing Summary & Sentiment
File numbers found in text: 333-123572
Letter
Re:
April 22, 2005
VIA FACSIMILE AND EDGAR
Securities and Exchange Commission
Division of Corporation Finance
450 Fifth Street, N.W.
Washington, D.C. 20549
Attention: Jeffrey P. Riedler, Assistant Director
Chemokine Therapeutics Corp.
Registration Statement on Form SB-2
(Commission File No. 333-123572)
Acceleration Request
Requested Date: Tuesday, April 26, 2005
Requested Time: 1:00 P.M. Eastern Time
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Chemokine Therapeutics Corp. (the "Registrant") hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to declare the above-captioned Registration Statement filed with the Commission on March 24, 2005, to become effective at the "Requested Date" and "Requested Time" set forth above or as soon as practicable thereafter.
The Registrant acknowledges that:
The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing;
Should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing and the Registrant may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
CHEMOKINE THERAPEUTICS CORP.
Show Raw Text
CORRESP 1 filename1.htm April 22, 2005 VIA FACSIMILE AND EDGAR Securities and Exchange Commission Division of Corporation Finance 450 Fifth Street, N.W. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: Chemokine Therapeutics Corp. Registration Statement on Form SB-2 (Commission File No. 333-123572) Acceleration Request Requested Date: Tuesday, April 26, 2005 Requested Time: 1:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Chemokine Therapeutics Corp. (the "Registrant") hereby requests that the Securities and Exchange Commission (the "Commission") take appropriate action to declare the above-captioned Registration Statement filed with the Commission on March 24, 2005, to become effective at the "Requested Date" and "Requested Time" set forth above or as soon as practicable thereafter. The Registrant acknowledges that: The action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Registrant from its full responsibility for the adequacy and accuracy of the disclosure in the filing; Should the Commission or the staff acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing and the Registrant may not assert this action as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, CHEMOKINE THERAPEUTICS CORP. /s/ Hassan Salari Chief Executive Officer Cc: Michael Reedich, SEC